These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

160 related items for PubMed ID: 2239487

  • 1. Madopar HBS (hydrodynamically balanced system) in the treatment of Parkinson's disease.
    Lees AJ.
    Adv Neurol; 1990; 53():475-82. PubMed ID: 2239487
    [No Abstract] [Full Text] [Related]

  • 2. Madopar HBS in nocturnal symptoms of Parkinson's disease.
    Jansen EN, Meerwaldtt JD.
    Adv Neurol; 1990; 53():527-31. PubMed ID: 2239493
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Open study of sustained-release formulation of levodopa and benserazide in parkinsonian patients.
    Kostić VS, Covicković-Sternić N.
    Neurologija; 1990; 39(2):99-105. PubMed ID: 2267052
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Madopar HBS in fluctuating parkinsonian patients: two-year treatment.
    Pezzoli G, Tesei S, Ferrante C, Cossutta E, Zecchinelli A, Scarlato G.
    Mov Disord; 1988; 3(1):37-45. PubMed ID: 3050471
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Sustained-release Madopar HBS compared with standard Madopar in the long-term treatment of de novo parkinsonian patients.
    Dupont E, Andersen A, Boas J, Boisen E, Borgmann R, Helgetveit AC, Kjaer MO, Kristensen TN, Mikkelsen B, Pakkenberg H, Presthus J, Stien R, Worm-Petersen J, Buch D.
    Acta Neurol Scand; 1996 Jan; 93(1):14-20. PubMed ID: 8825266
    [Abstract] [Full Text] [Related]

  • 13. A comparison of the effects of controlled-release levodopa (Madopar CR) with conventional levodopa in late Parkinson's disease.
    MacMahon DG, Sachdev D, Boddie HG, Ellis CJ, Kendal BR, Blackburn NA.
    J Neurol Neurosurg Psychiatry; 1990 Mar; 53(3):220-3. PubMed ID: 2182781
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Ten years' experience with enteral levodopa infusions for motor fluctuations in Parkinson's disease.
    Syed N, Murphy J, Zimmerman T, Mark MH, Sage JI.
    Mov Disord; 1998 Mar; 13(2):336-8. PubMed ID: 9539350
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.